Answers are grounded in this paper and cite their sources.
Background: Allergic bronchopulmonary aspergillosis (ABPA) is a complex pulmonary disorder caused by an immunological response to Aspergillus fumigatus antigen. Untreated patients develop recurrent exacerbations of respiratory symptoms, can develop bronchiectasis which progress to respiratory failure and permanent lung damage. Oral glucocorticoid taken over a period of weeks is currently the mainstay of treatment in acute ABPA in adults and children. However, there are some case reports suggesting the successful use of pulse doses of methylprednisolone among patients with ABPA, with underlying cystic fibrosis or asthma. Objective: This systematic review was undertaken to formulate guidelines for the use of pulsed methylprednisolone or pulsed dexamethasone for the treatment of acute ABPA in children with asthma. Methods: We first undertook a comprehensive literature search for preexisting high-quality guidelines addressing the issue to explore whether their recommendations could be adopted or adapted to our setting. Finding none, we conducted a systematic review of the literature to collate evidence comparing pulsed steroid therapy (methylprednisolone or dexamethasone) versus conventional oral steroid therapy for the treatment of acute ABPA in children with asthma. Results: Extensive literature search failed to identify any guidelines, systematic reviews, or randomized controlled trials addressing our question. Conclusion: Currently, there is no evidence comparing pulsed steroid therapy versus conventional oral therapy for acute ABPA in children with asthma, hence no evidence-based recommendation could be offered.
No takes yet. Share an insight, caveat, or question.
Mathew et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: